Magenta Lifecare Ltd IPO

If the company is unable to anticipate or respond to changing consumer preferences and trends pertaining to its products and foam industry in a timely and effective manner, the demand for its products may decline, which may have an adverse effect on its business, results of operations and financial condition.

The Company may be unable to implement new technologies for the company's business operations in a timely and cost-effective manner, or at all, which could adversely affect its business, results of operations, cash flows and financial condition.

The Company may be unable to obtain, renew or maintain statutory and regulatory permits, licenses and approvals required to operate its business and operate its manufacturing facilities, which could result in an adverse effect on its results of operations.

The company does not own its registered office and factory office from which the company carry out itsr business activities.

Any delay or default in payment from its distributors, dealer and customers could result in the reduction of its profits and affect the company cash flows.

The Company may not be able to sustain if there is no effective implementation of its business and growth strategy.

Its Promoter and the Promoter Group will jointly continue to retain majority shareholding in the Company after the issue, which will allow them to determine the outcome of the matters requiring the approval of shareholders.

Its Restated Financial Statements are prepared and signed by the Peer Review Auditor who is not Statutory Auditors of the Company as required under the provisions of SEBI (ICDR) Regulations 2018.

The company has entered into Related Party Transactions and continue to do so in future. There can be no assurance that such transactions, individually or in the aggregate, will not have an adverse effect on the Company's financial condition and results of operations.

Its ability to pay dividends in the future will depends upon its future earnings, financial condition, cash flows, working capital requirements, capital expenditure and restrictive covenants in its financing arrangements.